Fundraising Fox

Inceptor Bio

Morrisville, US · Founded 2020 · North Carolina LLC · 20 employees on LinkedIn · 1 known investors

Inceptor Bio is a clinical-stage biotechnology company developing cell therapies for cancer, focused on solid tumors. Its OUTLAST platform reprograms T cells during manufacturing to withstand the tumor microenvironment, and its lead candidate is IB-T101.

BiotechHealthtech

Founders & leadership

JL
Jason LawrenceExecutive
MSMatthias Schroff
Matthias SchroffExecutive
AS
Abraham S. MaingiExecutive
SMShailesh Maingi
Shailesh MaingiinFounder and ChairFounder, Managing Partner at Kineticos Life Sciences
DM
David Michael JohnstonNamed on SEC filing

Board

MBMark Bamforth
Mark BamforthinBoard directorGeneral Partner, KAMRA I Investment Committee Member at Kineticos Life Sciences
ES
Elizabeth SmithBoard director
GFGeorge Fotiades
George FotiadesinBoard directorStrategic Advisor at Kineticos Life Sciences
DH
Derek HenneckeinBoard MemberVenture Partner at Kineticos Life Sciences
MG
Mark GilbertBoard directorStrategic Advisor at Kineticos Life Sciences

Investors · 1

Kineticos DisruptorreportedRaleigh

Reported raises · per SEC filings

Form D private placements

$65.7M disclosed across 5 rounds · 2020–2025

▶$3.3MraisedJan 2025 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Abraham S. MaingiExecutive Officer
  • Elizabeth SmithDirector
  • Jason LawrenceExecutive Officer
  • Derek HenneckeDirector
  • Matthias SchroffExecutive Officer, Director
  • Shailesh MaingiDirector
  • George FotiadesDirector
  • Mark GilbertDirector
Offering amount
$3.4M
Amount sold
$3.3M
First sale
Jan 2025
Incorporated
Limited Liability Company, North Carolina, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.9MraisedJul 2024 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Elizabeth SmithDirector
  • Shailesh MaingiDirector
  • George FotiadesDirector
  • Derek HenneckeDirector
  • Mark GilbertDirector
  • Jason LawrenceExecutive Officer
  • Matthias SchroffExecutive Officer, Director
  • Abraham S. MaingiExecutive Officer
Offering amount
$15.9M
Amount sold
$15.9M
First sale
Oct 2022
Incorporated
Limited Liability Company, North Carolina, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$37.7MraisedMar 2022 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David Michael JohnstonDirector
  • Shailesh MaingiExecutive Officer, Director, Promoter
  • Mark BamforthDirector
  • Jason LawrenceExecutive Officer
  • Matthew John HainesExecutive Officer
  • Derek HenneckeDirector
  • Abraham Surinder MaingiExecutive Officer, Director
  • Michael NicholsonExecutive Officer
Offering amount
$60.8M
Amount sold
$37.7M
First sale
Feb 2022
Incorporated
Limited Liability Company, North Carolina, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.5MraisedJul 2021 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David Michael JohnstonDirector
  • Abraham Surinder MaingiExecutive Officer, Director
  • Shailesh MaingiExecutive Officer, Director, Promoter
  • Mark BamforthDirector
  • Derek HenneckeDirector
Offering amount
$18.1M
Amount sold
$5.5M
First sale
Jul 2021
Incorporated
Limited Liability Company, North Carolina, 2020
Federal exemptions
06b, 3C, 3C.1
Full filing on SEC EDGAR ↗
▶$3.3MraisedSep 2020 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Abraham Surinder MaingiExecutive Officer, Director
  • Shailesh MaingiPromoter
Offering amount
$3.3M
Amount sold
$3.3M
First sale
Apr 2020
Incorporated
Limited Liability Company, North Carolina, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Dispatch Biotherapeutics13 shared keywordsDispatch Bio develops a universal immunotherapy treatment for solid tumors, combining engineered immunotherapy with a tumor-specific virus to improve cancer treatment outcomes.

Companies competing with Inceptor Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Inceptor Bio Snags $37M for Three-Pronged Immuno-Oncology Platforms - BioSpacebiospace.com · May 2022Inceptor Bio Announces $37 Million Series A Financing - Inceptor Bioinceptor.bio · May 2022Triangle cell therapy startup Inceptor Bio closes $37M in Series A funding | WRAL TechWirewraltechwire.com · May 2022Inceptor Bio Announces $37 Million Series A Financing to Develop Cell Therapies for Difficult-to-Treat Cancersprnewswire.com · May 2022Inceptor Bio raises $26M seed round to fund gene therapies | Raleigh News & Observernewsobserver.com · Jun 2021Inceptor Bio adds to its coffers, bringing total to $3.2M raised since May | WRAL TechWirewraltechwire.com · Sep 2020

Frequently asked questions

What does Inceptor Bio do?
Inceptor Bio is a clinical-stage biotechnology company developing cell therapies for cancer, focused on solid tumors. Its OUTLAST platform reprograms T cells during manufacturing to withstand the tumor microenvironment, and its lead candidate is IB-T101.
Who are Inceptor Bio's investors?
Inceptor Bio's investors include Kineticos Disruptor.
How much funding has Inceptor Bio raised?
Inceptor Bio has disclosed $65.7M raised across 5 rounds.
Where is Inceptor Bio headquartered?
Inceptor Bio is headquartered in Morrisville, US.